Immunovant remains a high-risk, high-reward play, hinging on the success of its next-gen candidate IMVT-1402. IMVT-1402 shows promising Phase 1 data and convenient dosing but lacks direct patient ...
Immunovant, Inc. reported significant progress related to its lead asset IMVT-1402, having secured six Investigational New Drug applications and currently enrolling participants in pivotal studies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results